Recent FDA Approvals (through August/September 2010) related to Gilenya, Prolia, Krystexxa, Faslodex, Protopam Chloride, Ozurdex, Suboxone Film, Saphris, Tekamlo, Beyaz.
Fingolimod (Gilenya, Novartis) was the first approved oral treatment indicated for relapsing forms of multiple sclerosis.
Denosumab (Prolia, Amgen) was approved for the treatment of postmenopausal women with osteporosis at high risk for fracture.
Pegloticase (Krystexxa, Savient) was approved for the treatment of gout in adult patients refractory to conventional therapy.
Pralidoxime chloride (Protopam Chloride, Baxter Healthcare) was approved for the treatment of pesticide poisoning in children.
Dexamethasone intravitreal implant (Ozurdex, Allergan) 0.7 mg for the treatment of non-infectious ocular inflammation, or uveitis, affecting the posterior segment of the eye.
Buprenorphine and naloxone (Suboxone Film, Reckitt Benckiser Pharmaceuticals) sublingual film (C-III) was approved for the maintenance treatment of opioid dependence.
Asenapine (Saphris, Merck) sublingual tablets was approved for expanded indications and is now indicated for the treatment of schizophrenia in adults, as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, and as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
Aliskiren and amlodipine (Tekamlo, Novartis) single tablet was approved for the treatment of high blood pressure.
Estrogen/progestin combined oral contraceptive tablets that also contain a folate (levomefolate calcium 0.451 mg) (Beyaz, Bayer HealthCare) was approved for the prevention of pregnancy; treatment of symptoms of premenstrual dysphoric disorder in women who choose to use an oral contraceptive for contraception; and treatment of moderate acne vulgaris in women at least 14 years of age, only if the patient desires an oral contraceptive for birth control.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More